ABSI vs ACHV

Absci Corporation vs Achieve Life Sciences, Inc. — Valuation Comparison 2026

ABSI

Biotechnology
Absci Corporation
Quality
5.0
out of 10
Value Trap
29
LOW
Price
$6.08
Last close
Models
9/13
Active
VS

ACHV

Biotechnology
Achieve Life Sciences, Inc.
Quality
4.3
out of 10
Value Trap
30
LOW
Price
$5.30
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType ABSI Fair ValueABSI Upside ACHV Fair ValueACHV Upside
Bayesian DCF Intrinsic $1.65 -72.9% $1.57 -70.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.13 -97.8% $0.04 -99.0%
Dynamic NAV Asset-Based $1.02 -83.2% $0.41 -92.3%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ABSI vs ACHV — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ABSI vs ACHV — Which Stock Is More Undervalued?

ABSI scores higher with a 5.0/10 quality rating vs ACHV's 4.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Absci Corporation (ABSI) and Achieve Life Sciences, Inc. (ACHV) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ABSI currently trades at $6.08 with a QOC of 5.0/10, while ACHV trades at $5.30 with a QOC of 4.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).